Effects of CYP2C19 and CYP2C9 genotypes on pharmacokinetic variability of valproic acid in Chinese epileptic patients: Nonlinear mixed-effect modeling

European Journal of Clinical Pharmacology

Volumn 65, Issue 12, 2009, Pages 1187-1193

  Jiang, Dechun ^a,c   Bai, Xiangrong ^a   Zhang, Qingxia ^a   Lu, Wei ^b   Wang, Yuqin ^a   Li, Lin ^a   Müller, Markus ^c  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

CYP2C19; CYP2C9; Genotype; NONMEM; Population pharmacokinetics; Valproic acid

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; VALPROIC ACID;

ADOLESCENT; ADULT; AGED; ARTICLE; BIOLOGICAL MODEL; CHILD; CHINESE; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; EPILEPSY; FEMALE; GENOTYPE; HUMAN; INDIVIDUALIZATION; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL COMPUTING; MONOTHERAPY; PRESCHOOL CHILD; PRIORITY JOURNAL;

ADULT; AGED; ANTIMANIC AGENTS; ARYL HYDROCARBON HYDROXYLASES; CHINA; EPILEPSY; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NONLINEAR DYNAMICS; POPULATION; VALPROIC ACID; YOUNG ADULT;

EID: 71349084007     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-009-0712-x     Document Type: Article

References (35)

1. B Georges JM Conil T Seguin, et al. 2008 Cefepime in intensive care unit patients: validation of a population pharmacokinetic approach and influence of covariables Int J Clin Pharmacol Ther 46 157 164 1:CAS:528:DC%2BD1cXmtFygtrY%3D
2. PL Chan B Weatherley L McFadyen 2008 A population pharmacokinetic meta-analysis of maraviroc in healthy volunteers and asymptomatic HIV-infected subjects Br J Clin Pharmacol 65 Suppl 1 76 85 10.1111/j.1365-2125.2008.03139.x 1:CAS:528:DC%2BD1cXlt1CgtL8%3D
3. B Punyawudho RE Ramsay FM Macias, et al. 2008 Population pharmacokinetics of lamotrigine in elderly patients J Clin Pharmacol 48 455 463 10.1177/0091270007313391 1:CAS:528:DC%2BD1cXkslKntLs%3D
4. PC Ho FS Abbott UM Zanger, et al. 2003 Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes Pharmacogenomics J 3 335 342 10.1038/sj.tpj.6500210 1:CAS:528:DC%2BD3sXps1yiurw%3D (Pubitemid 38072171)
5. SM Jankovic JR Milovanovic 2007 Pharmacokinetic modeling of valproate from clinical data in Serbian epileptic patients Methods Find Exp Clin Pharmacol 29 673 679 10.1358/mf.2007.29.10.1116313 1:CAS:528:DC%2BD1cXislGhtrs%3D (Pubitemid 351251358)
6. DC Jiang L Wang YQ Wang, et al. 2007 Population pharmacokinetics of valproate in children with epilepsy in Chinese Acta Pharmacol Sin 28 1677 1684 10.1111/j.1745-7254.2007.00704.x 1:CAS:528:DC%2BD2sXhtFKjtrrJ (Pubitemid 47493299)
7. TK Kiang PC Ho MR Anari, et al. 2006 Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C91/1 genotype Toxicol Sci 94 261 271 10.1093/toxsci/kfl096 1:CAS:528:DC%2BD28XhtlWnsrjE (Pubitemid 44817142)
8. NA Panomvana D Ayudhya J Suwanmanee 2006 Pharmacokinetic parameters of total and unbound valproic acid and their relationships to seizure control in epileptic children Am J Ther 13 211 217 10.1097/01.mjt.0000155113.89092.58 (Pubitemid 44026188)
9. S Duffull T Waterhouse J Eccleston 2005 Some considerations on the design of population pharmacokinetic studies J Pharmacokinet Pharmacodyn 32 441 457 10.1007/s10928-005-0034-2 (Pubitemid 41738435)
10. B Meibohm S Laer JC Panetta 2005 Population pharmacokinetic studies in pediatrics: issues in design and analysis AAPS J 7 E475 E487 10.1208/aapsj070248 (Pubitemid 43071326)
11. SMF De Morais GR Wilkinson J Blaisdell, et al. 1994 The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans J Biol Chem 269 15419 15422
12. K Nasu T Kubota T Ishizaki 1997 Genetic analysis of CYP2C9 polymorphism in a Japanese population Pharmacogenetics 7 405 409 10.1097/00008571-199710000- 00011 1:CAS:528:DyaK2sXntVGks7g%3D (Pubitemid 27427552)
13. HG Xie 2000 Genetic variations of S-mephenytoin 4'-hydroxylase (CYP2C19) in the Chinese population Life Sci 66 175 181 10.1016/S0024-3205(00)00446-X (Pubitemid 30123210)
14. JQ Yang S Morin C Verstuyft, et al. 2003 Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations Fundam Clin Pharmacol 17 373 376 10.1046/j.1472-8206.2003.00148.x 1:CAS:528:DC%2BD3sXltFamu7Y%3D (Pubitemid 36774173)
15. K Ogungbenro L Aarons 2008 How many subjects are necessary for population pharmacokinetic experiments? Confidence interval approach Eur J Clin Pharmacol 64 705 713 10.1007/s00228-008-0493-7
16. C Dartois K Brendel E Comets, et al. 2007 Overview of model-building strategies in population PK/PD analyses: 2002-2004 literature survey Br J Clin Pharmacol 64 603 612 10.1111/j.1365-2125.2007.02975.x 1:STN:280: DC%2BD2sngvFGltA%3D%3D Comment in: Br J Clin Pharmacol 64: 578-579 (Pubitemid 47568828)
17. RJ Bauer S Guzy C Ng 2007 A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples AAPS J 9 E60 E83 10.1208/aapsj0901007 (Pubitemid 46404296)
18. BS Kappelhoff AD Huitema KM Crommentuyn, et al. 2005 Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patients Br J Clin Pharmacol 59 174 182 10.1111/j.1365-2125.2004.02241.x 1:CAS:528:DC%2BD2MXitFOgsLs%3D (Pubitemid 40208853)
19. K Mamiya I Ieiri J Shimamoto, et al. 1998 The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics Epilepsia 39 1317 1323 10.1111/j.1528-1157.1998.tb01330.x 1:CAS:528:DyaK1MXitFCjug%3D%3D (Pubitemid 29005631)
20. CC Hung CJ Lin CC Chen 2004 Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms Ther Drug Monit 26 534 540 10.1097/00007691-200410000-00012 1:CAS:528:DC%2BD2cXnslelsbo%3D (Pubitemid 39314322)
21. K Mamiya A Hadama E Yukawa, et al. 2000 CYP2C19 polymorphism effect on phenobarbitone. Pharmacokinetics in Japanese patients with epilepsy: analysis by population pharmacokinetics Eur J Clin Pharmacol 55 821 825 10.1007/s002280050703 1:CAS:528:DC%2BD3cXhslCjs70%3D
22. S Goto T Seo T Murata, et al. 2007 Population estimation of the effects of cytochrome P450 2C9 and 2C19 polymorphisms on phenobarbital clearance in Japanese Ther Drug Monit 29 118 121 10.1097/FTD.0b013e318030def0 1:CAS:528:DC%2BD2sXhslCmurw%3D (Pubitemid 46279885)
23. DC Jiang L Wang 2004 Population pharmacokinetic model of valproate and prediction of valproate serum concentrations in children with epilepsy Acta Pharmacol Sin 25 1576 1583 1:CAS:528:DC%2BD2cXhtFGitLfE
24. G Wang R Gu B Liu 2004 Population pharmacokinetics of valproic acid in children Chin J Hosp Pharm 24 735 738 1:CAS:528:DC%2BD2MXmtFOnur0%3D
25. ES El Desoky E Fuseau S El Din Amry 2004 Pharmacokinetic modeling of valproic acid from routine clinical data in Egyptian epileptic patients Eur J Clin Pharmacol 59 783 790 10.1007/s00228-003-0699-7 (Pubitemid 38221654)
26. Z Jiao MK Zhong M Hu, et al. 2004 Population pharmacokinetic modeling of valproic acid clearance Chin J Hosp Pharm 24 515 517 1:CAS:528: DC%2BD2MXkslKjt7c%3D
27. HM Park SS Kang YB Lee, et al. 2003 Population pharmacokinetics of intravenous valproic acid in Korean patients J Clin Pharm Ther 27 419 425 10.1046/j.1365-2710.2002.00440.x
28. E Yukawa T Nonaka M Yukawa 2003 Pharmacoepidemiologic investigation of a clonazepam-valproic acid interaction by mixed effect modeling using routine clinical pharmacokinetic data in Japanese patients J Clin Pharm Ther 28 497 504 10.1046/j.1365-2710.2003.00528.x 1:CAS:528:DC%2BD2cXmt1SrsQ%3D%3D (Pubitemid 38058133)
29. M Hu JH Zhang H Sun, et al. 2001 Construction and clinical application of the population pharmacokinetic model of valproic acid Evaluat Anal Drug-use Hosp China 1 95 97
30. KC Carlsson NO Hoem T Glauser 2005 Development of a population pharmacokinetic model for carbamazepine based on sparse therapeutic monitoring data from pediatric patients with epilepsy Clin Ther 27 618 626 10.1016/j.clinthera.2005.05.001 1:CAS:528:DC%2BD2MXht1WmtLfK (Pubitemid 40835973)
31. D Hirt B Van Overmeire JM Treluyer, et al. 2008 An optimized ibuprofen dosing scheme for preterm neonates with patent ductus arteriosus, based on a population pharmacokinetic and pharmacodynamic study Br J Clin Pharmacol 65 629 636 10.1111/j.1365-2125.2008.03118.x 1:CAS:528:DC%2BD1cXmsV2iurk%3D
32. C Nyakutira D Röshammar E Chigutsa, et al. 2008 High prevalence of the CYP2B6 516G->T(6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe Eur J Clin Pharmacol 64 357 365 10.1007/s00228-007-0412-3 1:CAS:528:DC%2BD1cXisFCmt78%3D
33. M Honda Y Ogura W Toyoda, et al. 2006 Multiple regression analysis of pharmacogenetic variability of carvedilol disposition in 54 healthy Japanese volunteers Biol Pharm Bull 29 772 778 10.1248/bpb.29.772 1:CAS:528: DC%2BD28XkslOit7Y%3D
34. VV Kumar SB Duffull 2008 Methods to account for inaccuracies in the dosing history when performing population pharmacokinetic analysis Pharm Res 25 2740 2749 10.1007/s11095-008-9638-8 1:CAS:528:DC%2BD1cXhsVeqsrbP
35. A Gunes E Bilir H Zengil 2007 Inhibitory effect of valproic acid on cytochrome P450 2C9 activity in epilepsy patients Basic Clin Pharmacol Toxicol 100 383 386 10.1111/j.1742-7843.2007.00061.x 1:CAS:528:DC%2BD2sXmvVaksLY%3D (Pubitemid 46776386)